Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
25 "Adrenal insufficiency"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Article
Adrenal gland
A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency
Suranut Charoensri, Richard J. Auchus
Endocrinol Metab. 2024;39(1):73-82.   Published online January 22, 2024
DOI: https://doi.org/10.3803/EnM.2024.1894
  • 5,215 View
  • 1,096 Download
  • 1 Web of Science
  • 3 Crossref
AbstractAbstract PDFPubReader   ePub   
Adrenal insufficiency (AI) can be classified into three distinct categories based on its underlying causes: primary adrenal disorders, secondary deficiencies in adrenocorticotropin, or hypothalamic suppression from external factors, most commonly glucocorticoid medications used for anti-inflammatory therapy. The hallmark clinical features of AI include fatigue, appetite loss, unintentional weight loss, low blood pressure, and hyponatremia. Individuals with primary AI additionally manifest skin hyperpigmentation, hyperkalemia, and salt craving. The diagnosis of AI is frequently delayed due to the non-specific symptoms and signs early in the disease course, which poses a significant challenge to its early detection prior to an adrenal crisis. Despite the widespread availability of lifesaving glucocorticoid medications for decades, notable challenges persist, particularly in the domains of timely diagnosis while simultaneously avoiding misdiagnosis, patient education for averting adrenal crises, and the determination of optimal replacement therapies. This article reviews recent advancements in the contemporary diagnostic strategy and approaches to optimal treatment for AI.

Citations

Citations to this article as recorded by  
  • Post-Traumatic Hypopituitarism
    Nissa Blocher
    Current Physical Medicine and Rehabilitation Reports.2024;[Epub]     CrossRef
  • Severe Fatigue in Uncontrolled Asthma: Contributing Factors and Impact of Rehabilitation
    Karin B. Fieten, Lianne ten Have, Linde N. Nijhof, Lucia Rijssenbeek-Nouwens, Anneke ten Brinke
    The Journal of Allergy and Clinical Immunology: In Practice.2024;[Epub]     CrossRef
  • Adrenal Insufficiency in Patients with Beta Thalassemia: A Meta-Analysis
    Christos Savvidis, Dimitra Ragia, Sophia Delicou, Aikaterini Xydaki, Manfredi Rizzo, Ioannis Ilias
    Medicina.2024; 60(10): 1571.     CrossRef
Close layer
Original Article
Miscellaneous
Incidence of Endocrine-Related Dysfunction in Patients Treated with New Immune Checkpoint Inhibitors: A Meta-Analysis and Comprehensive Review
Won Sang Yoo, Eu Jeong Ku, Eun Kyung Lee, Hwa Young Ahn
Endocrinol Metab. 2023;38(6):750-759.   Published online November 13, 2023
DOI: https://doi.org/10.3803/EnM.2023.1785
  • 2,733 View
  • 155 Download
  • 3 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
This study investigated the incidence of endocrine immune-related adverse events (irAEs) for recently developed immune checkpoint inhibitor (ICI) drugs.
Methods
We collected studies on newly developed ICI drugs using PubMed/Medline, Embase, and Cochrane Library from inception through January 31, 2023. Among ICI drugs, nivolumab, pembrolizumab, and ipilimumab were excluded from the new ICI drugs because many papers on endocrine-related side effects have already been published.
Results
A total of 44,595 patients from 177 studies were included in this analysis. The incidence of hypothyroidism was 10.1% (95% confidence interval [CI], 8.9% to 11.4%), thyrotoxicosis was 4.6% (95% CI, 3.8% to 5.7%), hypophysitis was 0.8% (95% CI, 0.5% to 1.1%), adrenal insufficiency was 0.9% (95% CI, 0.7% to 1.1%), and hyperglycemia was 2.3% (95% CI, 1.6% to 3.4%). Hypothyroidism and thyrotoxicosis occurred most frequently with programmed cell death protein-1 (PD-1) inhibitors (13.7% and 7.5%, respectively). The rate of endocrine side effects for the combination of a programmed death-ligand 1 inhibitor (durvalumab) and cytotoxic T lymphocyte-associated antigen 4 inhibitor (tremelimumab) was higher than that of monotherapy. In a meta-analysis, the combination of tremelimumab and durvalumab had a 9- to 10-fold higher risk of pituitary and adrenal-related side effects than durvalumab alone.
Conclusion
Newly developed PD-1 inhibitors had a high incidence of thyroid-related irAEs, and combined treatment with durvalumab and tremelimumab increased the risk of pituitary- and adrenal-related irAEs. Based on these facts, it is necessary to predict the endocrine side effects corresponding to each ICI drug, diagnose and treat them appropriately, and try to reduce the morbidity and mortality of patients.

Citations

Citations to this article as recorded by  
  • Start codon variant in LAG3 is associated with decreased LAG-3 expression and increased risk of autoimmune thyroid disease
    Saedis Saevarsdottir, Kristbjörg Bjarnadottir, Thorsteinn Markusson, Jonas Berglund, Thorunn A. Olafsdottir, Gisli H. Halldorsson, Gudrun Rutsdottir, Kristbjorg Gunnarsdottir, Asgeir Orn Arnthorsson, Sigrun H. Lund, Lilja Stefansdottir, Julius Gudmundsson
    Nature Communications.2024;[Epub]     CrossRef
  • Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Naoki Nishio, Shoi
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Pituitary Complications of Checkpoint Inhibitor Use
    Natalia Chamorro-Pareja, Alexander T Faje, Karen K Miller
    Endocrinology.2024;[Epub]     CrossRef
Close layer
Review Article
Adrenal Gland
Clinical and Technical Aspects in Free Cortisol Measurement
Man Ho Choi
Endocrinol Metab. 2022;37(4):599-607.   Published online August 19, 2022
DOI: https://doi.org/10.3803/EnM.2022.1549
  • 6,433 View
  • 354 Download
  • 18 Web of Science
  • 19 Crossref
AbstractAbstract PDFPubReader   ePub   
Accurate measurement of cortisol is critical in adrenal insufficiency as it reduces the risk associated with misdiagnosis and supports the optimization of stress dose. Comprehensive assays have been developed to determine the levels of bioactive free cortisol and their clinical and analytical efficacies have been extensively discussed because the level of total cortisol is affected by changes in the structure or circulating levels of corticoid-binding globulin and albumin, which are the main reservoirs of cortisol in the human body. Antibody-based immunoassays are routinely used in clinical laboratories; however, the lack of molecular specificity in cortisol assessment limits their applicability to characterize adrenocortical function. Improved specificity and sensitivity can be achieved by mass spectrometry coupled with chromatographic separation methods, which is a cutting-edge technology to measure individual as well as a panel of steroids in a single analytical run. The purpose of this review is to introduce recent advances in free cortisol measurement from the perspectives of clinical specimens and issues associated with prospective analytical technologies.

Citations

Citations to this article as recorded by  
  • Highly Responsive Bioassay for Quantification of Glucocorticoids
    Mathias Flensted Poulsen, Martin Overgaard, Christian Brix Folsted Andersen, Andreas Lodberg
    Analytical Chemistry.2024;[Epub]     CrossRef
  • An LC-MS/MS Method for the Simultaneous Quantification of Insulin, Cortisol, Glucagon-like Peptide 1, Ghrelin, and Osteocalcin
    Zhichao Zhang, Hareem Siddiqi, Yu-Ping Huang, Shannon McClorry, Peng Ji, Daniela Barile, Carolyn M. Slupsky
    Separations.2024; 11(2): 41.     CrossRef
  • Determination of cortisol cut-off limits and steroid dynamics in the ACTH stimulation test: a comparative analysis using Roche Elecsys Cortisol II immunoassay and LC-MS/MS
    Sema Okutan, Nanna Thurmann Jørgensen, Lars Engers Pedersen, Stina Willemoes Borresen, Linda Hilsted, Lennart Friis Hansen, Ulla Feldt-Rasmussen, Marianne Klose
    Endocrine.2024; 85(1): 321.     CrossRef
  • Advancements in Cortisol Detection: From Conventional Methods to Next-Generation Technologies for Enhanced Hormone Monitoring
    Visesh Vignesh, Bernardo Castro-Dominguez, Tony D. James, Julie M. Gamble-Turner, Stafford Lightman, Nuno M. Reis
    ACS Sensors.2024; 9(4): 1666.     CrossRef
  • Comparative analysis of salivary cortisol measurements using different assay methods in relation to serum-free cortisol measurement
    Anna Lee, Sooah Jang, Sanghoo Lee, Hyun-Kyung Park, In-Young Kim, Ryunsup Ahn, Jeong-Ho Seok, Kyoung-Ryul Lee
    Practical Laboratory Medicine.2024; 40: e00393.     CrossRef
  • A dilute and shoot method for urinary free cortisol analysis by LC-MS/MS
    Ying Shen, Xia Luo, Qing Guan, Liming Cheng
    Journal of Chromatography B.2024; 1239: 124127.     CrossRef
  • The role of thyroid hormones in assessing the survival of intensive care unit patients
    Daniela Bartolovic, Snezana Jovicic, Branka Terzic
    Vojnosanitetski pregled.2024; 81(5): 318.     CrossRef
  • Current Challenges and Future Directions in the Assessment of Glucocorticoid Status
    Sophie A Clarke, Pei Chia Eng, Alexander N Comninos, Katharine Lazarus, Sirazum Choudhury, Christie Tsang, Karim Meeran, Tricia M Tan, Waljit S Dhillo, Ali Abbara
    Endocrine Reviews.2024;[Epub]     CrossRef
  • Exaggerated Increases in the Serum Cortisol Level in a Woman Following Oral Contraceptive Treatment
    Run Yu
    AACE Clinical Case Reports.2024; 10(5): 206.     CrossRef
  • A systematic review and meta-analysis of cortisol levels in Plasmodium infections
    Kwuntida Uthaisar Kotepui, Frederick Ramirez Masangkay, Kinley Wangdi, Aongart Mahittikorn, Hideyuki J. Majima, Manas Kotepui
    Scientific Reports.2024;[Epub]     CrossRef
  • Effects of a veterinary functional music-based enrichment program on the psychophysiological responses of farm pigs
    Juliana Zapata Cardona, Santiago Duque Arias, Edimer David Jaramillo, Alexandre Surget, Yadira Ibargüen-Vargas, Berardo de Jesús Rodríguez
    Scientific Reports.2024;[Epub]     CrossRef
  • Post traumatic stress disorder associated hypothalamic-pituitary-adrenal axis dysregulation and physical illness
    Stephanie Lawrence, R. Hal Scofield
    Brain, Behavior, & Immunity - Health.2024; 41: 100849.     CrossRef
  • Neurobiological Implications of Chronic Stress and Metabolic Dysregulation in Inflammatory Bowel Diseases
    Aleksandar Sic, Kiana Cvetkovic, Eshanika Manchanda, Nebojsa Nick Knezevic
    Diseases.2024; 12(9): 220.     CrossRef
  • Osteopathic Manipulation as a Method of Cortisol Modification: A Systematic Review
    Dylan Thibaut, Valentine Santarlas, Joseph Hoppes, Alejandra Vásquez-Castillo, Alexa Morrow, Eddie Oviedo, James Toldi
    Cureus.2023;[Epub]     CrossRef
  • Pitfalls in the Diagnosis and Management of Hypercortisolism (Cushing Syndrome) in Humans; A Review of the Laboratory Medicine Perspective
    Kade C. Flowers, Kate E. Shipman
    Diagnostics.2023; 13(8): 1415.     CrossRef
  • Electrochemical sensors for cortisol detection: Principles, designs, fabrication, and characterisation
    Gopi Karuppaiah, Min-Ho Lee, Shekhar Bhansali, Pandiaraj Manickam
    Biosensors and Bioelectronics.2023; 239: 115600.     CrossRef
  • The role of the hypothalamic-pituitary-adrenal axis in depression across the female reproductive lifecycle: current knowledge and future directions
    Liisa Hantsoo, Kathleen M. Jagodnik, Andrew M. Novick, Ritika Baweja, Teresa Lanza di Scalea, Aysegul Ozerdem, Erin C. McGlade, Diana I. Simeonova, Sharon Dekel, Sara L. Kornfield, Michelle Nazareth, Sandra J. Weiss
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • РІВЕНЬ СТРЕСУ В ДІТЕЙ ШКІЛЬНОГО ВІКУ З COVID-19
    Г. А. Павлишин, О. І. Панченко
    Здобутки клінічної і експериментальної медицини.2023; (4): 119.     CrossRef
  • Corticotropin-stimulated steroid profiles to predict shock development and mortality in sepsis: From the HYPRESS study
    Josef Briegel, Patrick Möhnle, Didier Keh, Johanna M. Lindner, Anna C. Vetter, Holger Bogatsch, Dorothea Lange, Sandra Frank, Ludwig C. Hinske, Djillali Annane, Michael Vogeser, Michael Bauer, Thorsten Brenner, Patrick Meybohm, Markus Weigand, Matthias Gr
    Critical Care.2022;[Epub]     CrossRef
Close layer
Special Article
Miscellaneous
COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim, the Committee of Clinical Practice Guideline of the Korean Endocrine Society
Endocrinol Metab. 2021;36(4):757-765.   Published online August 17, 2021
DOI: https://doi.org/10.3803/EnM.2021.404
  • 11,584 View
  • 426 Download
  • 20 Web of Science
  • 21 Crossref
AbstractAbstract PDFPubReader   ePub   
Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders.

Citations

Citations to this article as recorded by  
  • COVID-19 mRNA vaccine may trigger subacute thyroiditis
    Mehmet Sözen, Ömercan Topaloğlu, Berrin Çetinarslan, Alev Selek, Zeynep Cantürk, Emre Gezer, Damla Köksalan, Taner Bayraktaroğlu
    Human Vaccines & Immunotherapeutics.2024; 17(12): 5120.     CrossRef
  • The role of co-morbidities in the development of an AEFI after COVID-19 vaccination in a large prospective cohort with patient-reported outcomes in the Netherlands
    C. Ouaddouh, J.W. Duijster, T. Lieber, F.P.A.M. van Hunsel
    Expert Opinion on Drug Safety.2024; 23(3): 323.     CrossRef
  • Thyroid dysfunction in COVID-19
    David Tak Wai Lui, Chi Ho Lee, Yu Cho Woo, Ivan Fan Ngai Hung, Karen Siu Ling Lam
    Nature Reviews Endocrinology.2024; 20(6): 336.     CrossRef
  • Adult-Onset Type 1 Diabetes Development Following COVID-19 mRNA Vaccination
    Hyeyeon Moon, Sunghwan Suh, Mi Kyoung Park
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Prior immunization status of COVID-19 patients and disease severity: A multicenter retrospective cohort study assessing the different types of immunity
    Javaria Aslam, Faisal Shahzad Khan, Muhammad Talha Haris, Hewad Hewadmal, Maryam Khalid, Mohammad Y. Alshahrani, Qurrat-ul-ain Aslam, Irrum Aneela, Urooj Zafar
    Vaccine.2023; 41(2): 598.     CrossRef
  • Mortality and Severity of Coronavirus Disease 2019 in Patients with Long-Term Glucocorticoid Therapy: A Korean Nationwide Cohort Study
    Eu Jeong Ku, Keeho Song, Kyoung Min Kim, Gi Hyeon Seo, Soon Jib Yoo
    Endocrinology and Metabolism.2023; 38(2): 253.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • Inactivated SARS-CoV-2 vaccination does not disturb the clinical course of Graves’ disease: An observational cohort study
    Shichen Xu, Huixin Yu, Xian Cheng, Jing Wu, Jiandong Bao, Li Zhang
    Vaccine.2023; 41(38): 5648.     CrossRef
  • Adrenal Crisis Associated With COVID-19 Vaccination in Patients With Adrenal Insufficiency
    Yukako Kurematsu, Takako Mohri, Sadanori Okada, Yutaka Takahashi
    JCEM Case Reports.2023;[Epub]     CrossRef
  • Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
    İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı
    Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248.     CrossRef
  • Neue Aspekte der Glukokortikoidsubstitution bei Nebennierenrindeninsuffizienz
    Tina Kienitz, Gesine Meyer
    Der Internist.2022; 63(1): 12.     CrossRef
  • Endocrine Follow-up During Post-Acute COVID-19: Practical Recommendations Based on Available Clinical Evidence
    Rimesh Pal, Ameya Joshi, Sanjay K. Bhadada, Mainak Banerjee, Suresh Vaikkakara, Satinath Mukhopadhyay
    Endocrine Practice.2022; 28(4): 425.     CrossRef
  • Safety of Inactivated and mRNA COVID-19 Vaccination Among Patients Treated for Hypothyroidism: A Population-Based Cohort Study
    Xi Xiong, Carlos King Ho Wong, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Franco Wing Tak Cheng, Kristy Tsz Kwan Lau, Chi Ho Lee, Yu Cho Woo, David Tak Wai Lui, Ian Chi Kei Wong
    Thyroid.2022; 32(5): 505.     CrossRef
  • The New Entity of Subacute Thyroiditis amid the COVID-19 Pandemic: From Infection to Vaccine
    Mihaela Popescu, Adina Ghemigian, Corina Maria Vasile, Andrei Costache, Mara Carsote, Alice Elena Ghenea
    Diagnostics.2022; 12(4): 960.     CrossRef
  • Adrenal Crisis Secondary to COVID-19 Vaccination in a Patient With Hypopituitarism
    Nikolina Markovic, Anila Faizan, Chirag Boradia, Sridhar Nambi
    AACE Clinical Case Reports.2022; 8(4): 171.     CrossRef
  • The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
    LingHong Huang, ZhengRong Jiang, JingXiong Zhou, YuPing Chen, HuiBin Huang
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Osteoporosis in Patients With Respiratory Diseases
    Yue Ma, Shui Qiu, Renyi Zhou
    Frontiers in Physiology.2022;[Epub]     CrossRef
  • Pilot Findings on SARS-CoV-2 Vaccine-Induced Pituitary Diseases: A Mini Review from Diagnosis to Pathophysiology
    Ach Taieb, El Euch Mounira
    Vaccines.2022; 10(12): 2004.     CrossRef
  • Forty Years Together, New Leap Forward! The 40th Anniversary of the Korean Endocrine Society
    Jong Chul Won, Ki-Hyun Baek
    Endocrinology and Metabolism.2022; 37(6): 851.     CrossRef
  • No need of glucocorticoid dose adjustment in patients with adrenal insufficiency before COVID-19 vaccine
    Tania Pilli, Cristina Dalmiglio, Gilda Dalmazio, Alfonso Sagnella, Raffaella Forleo, Lucia Brilli, Fabio Maino, Cristina Ciuoli, Maria Grazia Castagna
    European Journal of Endocrinology.2022; 187(1): K7.     CrossRef
  • Diabetes and COVID-19 Vaccination
    Hae Dong Choi, Jun Sung Moon
    The Journal of Korean Diabetes.2021; 22(4): 221.     CrossRef
Close layer
Review Article
Miscellaneous
Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors
Shintaro Iwama, Tomoko Kobayashi, Hiroshi Arima
Endocrinol Metab. 2021;36(2):312-321.   Published online April 27, 2021
DOI: https://doi.org/10.3803/EnM.2021.1007
  • 6,468 View
  • 283 Download
  • 21 Web of Science
  • 18 Crossref
AbstractAbstract PDFPubReader   ePub   
Immune-related adverse events (irAEs) affecting the endocrine glands are among the most frequent irAEs induced by immune checkpoint inhibitors (ICIs) and include hypopituitarism, primary adrenal insufficiency, thyrotoxicosis, hypothyroidism, hypoparathyroidism, and type 1 diabetes mellitus. Since the incidence and clinical features of endocrine irAEs vary according to the ICI used, it is important to understand the characteristics of these irAEs and to manage each one appropriately. Since some endocrine irAEs, including adrenal crisis and diabetic ketoacidosis, are potentially life-threatening, predicting the risk of endocrine irAEs before their onset is critical. Several autoantibodies have been detected in patients who develop endocrine irAEs, among which anti-thyroid antibodies may be predictive biomarkers of thyroid dysfunction. In this review, we describe the clinical features of each endocrine irAE induced by ICIs and discuss their potential biomarkers, including autoantibodies.

Citations

Citations to this article as recorded by  
  • Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
    Tomoko Kobayashi, Shintaro Iwama, Hiroshi Arima
    Endocrine Journal.2024; 71(1): 23.     CrossRef
  • A case of rapidly progressive insulin-dependent diabetes mellitus without islet autoantibodies developed over two years after the first dose of nivolumab
    Kota Nishihama, Yuko Okano, Chisa Inoue, Kanako Maki, Kazuhito Eguchi, Soichiro Tanaka, Atsuro Takeshita, Mei Uemura, Taro Yasuma, Toshinari Suzuki, Esteban C. Gabazza, Yutaka Yano
    Diabetology International.2024; 15(3): 583.     CrossRef
  • Endocrinopathies Associated With Immune Checkpoint Inhibitor Use
    Anupam Kotwal, Randol Kennedy, Nupur Kikani, Sonali Thosani, Whitney Goldner, Afreen Shariff
    Endocrine Practice.2024; 30(6): 584.     CrossRef
  • Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Tetsushi Izuchi, Koji Suzuki, Koki Otake, Yoshinori Yasuda, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Naoki Nishio, Shoi
    Cancer Immunology, Immunotherapy.2024;[Epub]     CrossRef
  • Adrenal Insufficiency and Thyrotoxicosis Following Combined Immune Checkpoint Inhibitor Use: A Case Report and Literature Review
    Kaoruko Fukushima, Saori Kitayama, Manami Sazuka, Remi Kodera, Kazuhito Oba, Kenji Toyoshima, Yuko Chiba, Hiroshi Yamamoto, Atsushi Araki, Yoshiaki Tamura
    Cureus.2024;[Epub]     CrossRef
  • Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade
    Ayana Yamagami, Shintaro Iwama, Tomoko Kobayashi, Xin Zhou, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Tetsushi Izuchi, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Hiroshi Arima
    Endocrine Journal.2024; 71(5): 515.     CrossRef
  • Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer
    Shusu Liu, Peiyu Lu, Bixia Yang, Yan Yang, Hua Zhou, Min Yang
    BMC Nephrology.2024;[Epub]     CrossRef
  • Recovery from insulin dependence in immune checkpoint inhibitor‐associated diabetes mellitus: A case report
    Marie Okubo, Yuji Hataya, Kanta Fujimoto, Toshio Iwakura, Naoki Matsuoka
    Journal of Diabetes Investigation.2023; 14(1): 147.     CrossRef
  • Case Report: A Rising Cause of New-Onset Endocrinopathies After Immunotherapy
    Charity Tan, Sarah Hendricks, Kristina Hernandez, Martha Benavides, Rupinderjit Samra
    The Journal for Nurse Practitioners.2023; 19(5): 104582.     CrossRef
  • Risk of Thyroid Dysfunction in PD-1 Blockade Is Stratified by the Pattern of TgAb and TPOAb Positivity at Baseline
    Xin Zhou, Shintaro Iwama, Tomoko Kobayashi, Masahiko Ando, Hiroshi Arima
    The Journal of Clinical Endocrinology & Metabolism.2023; 108(10): e1056.     CrossRef
  • Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
    Liman Huo, Chao Wang, Haixia Ding, Xuelian Shi, Bin Shan, Ruoying Zhou, Ping Liang, Juan Hou
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy
    Aleksandra Basek, Grzegorz K. Jakubiak, Grzegorz Cieślar, Agata Stanek
    Cancers.2023; 15(24): 5786.     CrossRef
  • Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline
    Shintaro Iwama, Tomoko Kobayashi, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Masahiko Ando, Xin Zhou, Ayana Yamagami, Takeshi Onoue, Yohei Kawaguchi, Takashi Miyata, Mariko Sugiyama, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tets
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(4): e1620.     CrossRef
  • Biomarkers and risk factors for the early prediction of immune-related adverse events: a review
    Ying Zhang, Xiaoling Zhang, Weiling Li, Yunyi Du, Wenqing Hu, Jun Zhao
    Human Vaccines & Immunotherapeutics.2022;[Epub]     CrossRef
  • Immune Checkpoint Inhibitors as a Threat to the Hypothalamus–Pituitary Axis: A Completed Puzzle
    Agnese Barnabei, Andrea Corsello, Rosa Maria Paragliola, Giovanni Maria Iannantuono, Luca Falzone, Salvatore Maria Corsello, Francesco Torino
    Cancers.2022; 14(4): 1057.     CrossRef
  • Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade
    Tomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, Yoshinori Yasuda, Takayuki Okuji, Masaaki Ito, Xin Zhou, Masahiko Ando, Takeshi Onoue, Takashi Miyata, Mariko Sugiyama, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Tetsunari Hase, Masahiro Morise, Taka
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(10): e4115.     CrossRef
  • Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors
    Fabiana Pani, Yoshinori Yasuda, Sylvie T Rousseau, Kevin C Bermea, Solmaz Roshanmehr, Rulin Wang, Srinivasan Yegnasubramanian, Patrizio Caturegli, Luigi Adamo
    Journal for ImmunoTherapy of Cancer.2022; 10(12): e005538.     CrossRef
  • Survival benefit of endocrine dysfunction following immune checkpoint inhibitors for nonthyroidal cancers
    Anupam Kotwal, Mabel Ryder
    Current Opinion in Endocrinology, Diabetes & Obesity.2021; 28(5): 517.     CrossRef
Close layer
Original Article
Clinical Study
Stimulated Salivary Cortisol as a Noninvasive Diagnostic Tool for Adrenal Insufficiency
Yoon Ji Kim, Jung Hee Kim, A Ram Hong, Kyeong Seon Park, Sang Wan Kim, Chan Soo Shin, Seong Yeon Kim
Endocrinol Metab. 2020;35(3):628-635.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.707
  • 6,844 View
  • 216 Download
  • 14 Web of Science
  • 15 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Salivary cortisol is routinely used as a diagnostic test for Cushing syndrome. The diagnostic use of salivary cortisol for adrenal insufficiency (AI), however, is less established. We aimed to investigate the utility of morning basal and adrenocorticotropic hormone-stimulated salivary cortisol in diagnosing AI in Korean adults.
Methods
We prospectively included 120 subjects (female, n=70) from Seoul National University Hospital. AI was defined as a stimulated serum cortisol level of <496.8 nmol/L during the short Synacthen test (SST). Serum and saliva samples were drawn between 8:00 AM and 10:00 AM. Salivary cortisol levels were measured using an enzyme immunoassay kit.
Results
Thirty-four patients were diagnosed with AI according to the SST results. Age, sex, body mass index, serum albumin levels, and serum creatinine levels did not significantly differ between the normal and AI groups. Basal and stimulated salivary cortisol levels were positively correlated with basal (r=0.538) and stimulated serum cortisol levels (r=0.750), respectively (all P<0.001). Receiver operating characteristic curve analysis yielded a cutoff level of morning basal salivary cortisol of 3.2 nmol/L (sensitivity, 84.9%; specificity, 73.5%; area under the curve [AUC]=0.822). The optimal cutoff value of stimulated salivary cortisol was 13.2 nmol/L (sensitivity, 90.7%; specificity, 94.1%; AUC=0.959). Subjects with a stimulated salivary cortisol level above 13.2 nmol/L but a stimulated serum cortisol level below 496.8 nmol/L (n=2) had lower serum albumin levels than those showing a concordant response.
Conclusion
The diagnostic performance of stimulated salivary cortisol measurements after the SST was comparable to serum cortisol measurements for diagnosing AI.

Citations

Citations to this article as recorded by  
  • Extensive Expertise in Endocrinology: Adrenal crisis in assisted reproduction and pregnancy
    Ulla Feldt-Rasmussen
    European Journal of Endocrinology.2024;[Epub]     CrossRef
  • Turning Antibodies into Ratiometric Bioluminescent Sensors for Competition-Based Homogeneous Immunoassays
    Eva A. van Aalen, Joep J. J. Lurvink, Leandra Vermeulen, Benice van Gerven, Yan Ni, Remco Arts, Maarten Merkx
    ACS Sensors.2024; 9(3): 1401.     CrossRef
  • A Contemporary Approach to the Diagnosis and Management of Adrenal Insufficiency
    Suranut Charoensri, Richard J. Auchus
    Endocrinology and Metabolism.2024; 39(1): 73.     CrossRef
  • Insuficiencia suprarrenal
    A.E. Ortiz-Flores, M. Araujo-Castro, E. Pascual-Corrales, H.F. Escobar-Morreale
    Medicine - Programa de Formación Médica Continuada Acreditado.2024; 14(13): 718.     CrossRef
  • Utility of Salivary Cortisol and Cortisone in the Diagnostics of Adrenal Insufficiency
    Kåre Kvam Hellan, Martin Lyngstad, Paal Methlie, Kristian Løvås, Eystein Sverre Husebye, Grethe Åstrøm Ueland
    The Journal of Clinical Endocrinology & Metabolism.2024;[Epub]     CrossRef
  • Post-Traumatic Hypopituitarism
    Nissa Blocher
    Current Physical Medicine and Rehabilitation Reports.2024;[Epub]     CrossRef
  • Diagnostic strategies in adrenal insufficiency
    Vasiliki Siampanopoulou, Elisavet Tasouli, Anna Angelousi
    Current Opinion in Endocrinology, Diabetes & Obesity.2023; 30(3): 141.     CrossRef
  • The association between neuropeptide oxytocin and neuropsychiatric disorders after orthopedic surgery stress in older patients
    Wanru Dong, Zengbo Ding, Xiao Wu, Ran Wan, Ying Liu, Liubao Pei, Weili Zhu
    BMC Geriatrics.2023;[Epub]     CrossRef
  • The Reliability of Salivary Cortisol Compared to Serum Cortisol for Diagnosing Adrenal Insufficiency with the Gold Standard ACTH Stimulation Test in Children
    Silvia Ciancia, Sjoerd A. A. van den Berg, Erica L. T. van den Akker
    Children.2023; 10(9): 1569.     CrossRef
  • РІВЕНЬ СТРЕСУ В ДІТЕЙ ШКІЛЬНОГО ВІКУ З COVID-19
    Г. А. Павлишин, О. І. Панченко
    Здобутки клінічної і експериментальної медицини.2023; (4): 119.     CrossRef
  • Secondary adrenal suppression related to high doses of inhaled corticosteroids in patients with severe asthma
    Mariana Lobato, João Gaspar-Marques, Pedro Carreiro-Martins, Paula Leiria-Pinto
    Annals of Allergy, Asthma & Immunology.2022; 128(4): 464.     CrossRef
  • Clinical and Technical Aspects in Free Cortisol Measurement
    Man Ho Choi
    Endocrinology and Metabolism.2022; 37(4): 599.     CrossRef
  • Continuous biomarker monitoring with single molecule resolution by measuring free particle motion
    Alissa D. Buskermolen, Yu-Ting Lin, Laura van Smeden, Rik B. van Haaften, Junhong Yan, Khulan Sergelen, Arthur M. de Jong, Menno W. J. Prins
    Nature Communications.2022;[Epub]     CrossRef
  • Reversible Immunosensor for the Continuous Monitoring of Cortisol in Blood Plasma Sampled with Microdialysis
    Laura van Smeden, Annet Saris, Khulan Sergelen, Arthur M. de Jong, Junhong Yan, Menno W. J. Prins
    ACS Sensors.2022; 7(10): 3041.     CrossRef
  • Adrenal insufficiency in HIV/AIDS: a review
    Simon Mifsud, Zachary Gauci, Mark Gruppetta, Charles Mallia Azzopardi, Stephen Fava
    Expert Review of Endocrinology & Metabolism.2021; 16(6): 351.     CrossRef
Close layer
Review Article
Miscellaneous
Encountering COVID-19 as Endocrinologists
Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee
Endocrinol Metab. 2020;35(2):197-205.   Published online June 23, 2020
DOI: https://doi.org/10.3803/EnM.2020.35.2.197
  • 14,257 View
  • 296 Download
  • 15 Web of Science
  • 17 Crossref
AbstractAbstract PDFPubReader   ePub   
The world is entering an era of disaster and chaos due to coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2. Since its first emergence in December 2019 in Wuhan, China, COVID-19 has swept through Asia and propagated throughout the world to Europe and North America. As of April 13, 1,773,084 people were infected and 111,652 people had died from COVID-19 globally, and new record levels of infection are being reported every day. Based on the data that have been amassed so far, the primary risk factors for a severe disease course or even mortality from COVID-19 are underlying diseases such as diabetes and hypertension. As the global prevalence of diabetes continues to increase, patients with endocrine diseases such as diabetes mellitus and those who are on long-term corticosteroid therapy due to adrenal insufficiency or hypopituitarism are at risk for a poor prognosis of COVID-19. As endocrinologists, we would like to briefly review the current knowledge about the relationship between COVID-19 and endocrine diseases and to discuss what we can do for the safety and health of our patients with endocrine diseases in this globally threatening situation.

Citations

Citations to this article as recorded by  
  • Recent advances in the development of multiplexed nanophotonic biosensors.
    Z.K.S. Mcotshana, L.N. Thwala, M.H.C. Tlomatsane, E. van Steen, P. Mthunzi-Kufa
    Photodiagnosis and Photodynamic Therapy.2024; 48: 104246.     CrossRef
  • Determining the frequency of thyroid involvement in chest CT scans of COVID-19 patients and its correlation with the severity of lung involvement and survival of patients in 2020
    Fatemeh Yarmahmoodi, Shoayb Samimi, Banafasheh Zeinali-Rafsanjani, Seyed Mostajab Razavinejad, Mahdi Saeedi-Moghadam
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • Adverse Events Associated with COVID-19 Vaccination in Adolescents with Endocrinological Disorders: A Cross-Sectional Study
    İbrahim Mert Erbaş, İrem Ceren Erbaş, Gözde Akın Kağızmanlı, Kübra Yüksek Acinikli, Özge Besci, Korcan Demir, Ece Böber, Nurşen Belet, Ayhan Abacı
    Journal of Clinical Research in Pediatric Endocrinology.2023; 15(3): 248.     CrossRef
  • Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study
    Jeonghoon Ha, Kyoung Min Kim, Dong-Jun Lim, Keeho Song, Gi Hyeon Seo
    Journal of Clinical Medicine.2023; 12(14): 4799.     CrossRef
  • New-onset and relapsed Graves’ disease following COVID-19 vaccination: a comprehensive review of reported cases
    Kan Chen, Yiyang Gao, Jing Li
    European Journal of Medical Research.2023;[Epub]     CrossRef
  • Assessment of Neuroendocrine Changes and Hypothalamo-Pituitary Autoimmunity in Patients with COVID-19
    Mustafa Sait Gonen, Annamaria De Bellis, Emre Durcan, Giuseppe Bellastella, Paolo Cirillo, Lorenzo Scappaticcio, Miriam Longo, Basak Ecem Bircan, Serdar Sahin, Cem Sulu, Hande Mefkure Ozkaya, Dildar Konukoglu, Fatma Ferda Kartufan, Fahrettin Kelestimur
    Hormone and Metabolic Research.2022; 54(03): 153.     CrossRef
  • COVID-19 and diabetes: Association intensify risk factors for morbidity and mortality
    Prateek Sharma, Tapan Behl, Neelam Sharma, Sukhbir Singh, Ajmer Singh Grewal, Ali Albarrati, Mohammed Albratty, Abdulkarim M. Meraya, Simona Bungau
    Biomedicine & Pharmacotherapy.2022; 151: 113089.     CrossRef
  • The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess—The CAPISCO International Expert Panel
    Mojca Jensterle, Rok Herman, Andrej Janež, Wael Al Mahmeed, Khalid Al-Rasadi, Kamila Al-Alawi, Maciej Banach, Yajnavalka Banerjee, Antonio Ceriello, Mustafa Cesur, Francesco Cosentino, Massimo Galia, Su-Yen Goh, Sanjay Kalra, Peter Kempler, Nader Lessan,
    International Journal of Molecular Sciences.2022; 23(13): 7326.     CrossRef
  • WhatsApp-Based Virtual Consultation in Clinical Practice during COVID Times
    Ramakanth Bhargav Panchangam, Pradeep Puthenveetil, Sunil Kumar Kota, Sabaretnam Mayilvaganan
    Annals of African Medicine.2022; 21(2): 132.     CrossRef
  • Thyroid and COVID-19: a review on pathophysiological, clinical and organizational aspects
    G. Lisco, A. De Tullio, E. Jirillo, V. A. Giagulli, G. De Pergola, E. Guastamacchia, V. Triggiani
    Journal of Endocrinological Investigation.2021; 44(9): 1801.     CrossRef
  • Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
    Sang Youl Rhee, Jeongwoo Lee, Hyewon Nam, Dae-Sung Kyoung, Dong Wook Shin, Dae Jung Kim
    Diabetes & Metabolism Journal.2021; 45(2): 251.     CrossRef
  • COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
    Cheol Ryong Ku, Kyong Yeun Jung, Chang Ho Ahn, Jun Sung Moon, Ju Hee Lee, Eun Heui Kim, Hyemi Kwon, Hee Kyung Kim, Sunghwan Suh, Sangmo Hong, Jeonghoon Ha, Eun Roh, Jin Hwa Kim, Mi-kyung Kim
    Endocrinology and Metabolism.2021; 36(4): 757.     CrossRef
  • Collateral Damage of the COVID‐19 Pandemic on Nutritional Quality and Physical Activity: Perspective from South Korea
    Soo Lim, Hyunjung Lim, Jean‐Pierre Després
    Obesity.2020; 28(10): 1788.     CrossRef
  • Diabetes mellitus and COVID-19 in the post-acute phase patients - possible links with physical and rehabilitation medicine and balneotherapy
    Constantin Munteanu, Diana-Loreta PĂUN, Alina-Maria ȘUȚĂ, Simin Aysel FLORESCU, Gelu ONOSE, Mihail Hoteteu
    Balneo Research Journal.2020; 11(Vol.11, no): 350.     CrossRef
  • Managing Diabetes During the COVID-19 Pandemic
    John Doupis, Konstantinos Avramidis
    European Endocrinology.2020; 16(2): 85.     CrossRef
  • Independent Impact of Diabetes on the Severity of Coronavirus Disease 2019 in 5,307 Patients in South Korea: A Nationwide Cohort Study
    Sun Joon Moon, Eun-Jung Rhee, Jin-Hyung Jung, Kyung-Do Han, Sung-Rae Kim, Won-Young Lee, Kun-Ho Yoon
    Diabetes & Metabolism Journal.2020; 44(5): 737.     CrossRef
  • SARS-CoV-2 (COVID-19) and the Endocrine System
    Michelle D Lundholm, Caroline Poku, Nicholas Emanuele, Mary Ann Emanuele, Norma Lopez
    Journal of the Endocrine Society.2020;[Epub]     CrossRef
Close layer
Original Articles
Clinical Characteristics of Patients with Adrenal Insufficiency in a General Hospital
Ye Yeon Lee, Nan Hee Cho, Jong Won Lee, Nam Kyung Kim, Hye Soon Kim, Mi-Kyung Kim
Endocrinol Metab. 2017;32(1):83-89.   Published online February 28, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.83
  • 5,148 View
  • 62 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   
Background

Adrenal insufficiency (AI) is a life-threatening disorder caused by the deficiency of adrenal steroid hormones. This retrospective cross-sectional study investigated the characteristics of patients with AI in Korea.

Methods

All consecutive patients with suspected AI who received care at a tertiary referral center in Korea in 2014 and underwent adrenocorticotropic hormone stimulation or insulin-tolerance testing were identified through a review of medical charts. Patients diagnosed with AI were enrolled. Their demographic, clinical, and treatment details were extracted.

Results

Of 771 patients with suspected AI, 183 (23.7%) received a definitive diagnosis. The most common reason for testing was the presence of suspicious AI-related symptoms (30.0%), followed by a history of steroid medications (23.5%). Their mean age was 66.7 years, and females predominated (67.8%). The most common symptoms were general weakness, anorexia, arthralgia, and fever. Approximately half (53.6%) had a history of steroid use. Hydrocortisone was the most common treatment (71.6%), with most patients taking a 30 mg dose (44.2%). The most common dose frequency was twice a day (78.6%). Fourteen patients were treated for adrenal crisis (n=10, 5.5%) or an intercurrent illness (n=4, 2.2%).

Conclusion

AI may have been caused by steroid medication use in many of the patients included in this study. The detection of AI can be improved by careful history-taking and being alert to the possibility that a patient has used steroids.

Citations

Citations to this article as recorded by  
  • Risk of Mental Illnesses in Patients With Hypopituitarism: A Nationwide Population-Based Cohort Study
    I-Hua Wei, Chih-Chia Huang
    Psychiatry Investigation.2022; 19(6): 418.     CrossRef
  • The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events
    Bradley D. Menz, Jacinta L. Johnson, Davina F. Gillard, William Chong, Michael B. Ward
    Journal of Pharmacy Practice.2021; 34(3): 386.     CrossRef
  • Clinical and biochemical factors to predict biochemical adrenal insufficiency in hospitalized patients with indeterminate cortisol levels: a retrospective study
    Worapaka Manosroi, Natapong Kosachunhanan, Pichitchai Atthakomol
    BMC Endocrine Disorders.2020;[Epub]     CrossRef
  • Possible adrenal insufficiency among fatigue patients in a psychosomatic medical clinic
    Sunao Matsubayashi, Nobuhiro Nakatake, Takeshi Hara
    Endocrine Journal.2020; 67(1): 53.     CrossRef
  • Encountering COVID-19 as Endocrinologists
    Eun-Jung Rhee, Jung Hee Kim, Sun Joon Moon, Won-Young Lee
    Endocrinology and Metabolism.2020; 35(2): 197.     CrossRef
  • Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data
    Kamran Iqbal, Kate Halsby, Robert D Murray, Paul V Carroll, Robert Petermann
    Endocrine Connections.2019; 8(1): 20.     CrossRef
Close layer
Clinical Study
Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal Insufficiency
Jong Ha Baek, Soo Kyoung Kim, Jung Hwa Jung, Jong Ryeal Hahm, Jaehoon Jung
Endocrinol Metab. 2016;31(1):153-160.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.153
  • 5,742 View
  • 93 Download
  • 13 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   
Background

The chronic use of glucocorticoids (GC) suppresses function of the hypothalamic-pituitary-adrenal axis and often results in secondary adrenal insufficiency (AI). The present study aimed to determine the recovery rate of adrenal function in patients with secondary AI within 1 to 2 years and to assess the factors predictive of adrenal function recovery.

Methods

This was a retrospective observational study that enrolled patients diagnosed with GC-induced secondary AI between 2007 and 2013. AI was defined by peak serum cortisol levels <18 µg/dL during a standard-dose short synacthen test (SST). A follow-up SST was performed after 1 to 2 years, and responders were defined as those with adrenocorticotropic hormone (ACTH)-stimulated peak serum cortisol levels ≥18 µg/dL.

Results

Of the total 34 patients diagnosed with GC-induced secondary AI at first, 20 patients (58.8%) recovered normal adrenal function by the time of the follow-up SST (median follow-up period, 16.5 months). Although the baseline serum ACTH and cortisol levels at the first SST did not differ between responders and non-responders, the incremental cortisol response during the first SST was higher in responders than that of non-responders (7.88 vs. 3.56, P<0.01). Additionally, higher cortisol increments during the first SST were an independent predictive factor of the adrenal function recovery (odds ratio, 1.58; 95% confidence interval, 1.02 to 2.46; P<0.05).

Conclusion

In the present study, adrenal function recovery was achieved frequently in patients with GC-induced secondary AI within 1 to 2 years. Additionally, an incremental cortisol response at the first SST may be an important predictive factor of adrenal function recovery.

Citations

Citations to this article as recorded by  
  • European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency
    Felix Beuschlein, Tobias Else, Irina Bancos, Stefanie Hahner, Oksana Hamidi, Leonie van Hulsteijn, Eystein S Husebye, Niki Karavitaki, Alessandro Prete, Anand Vaidya, Christine Yedinak, Olaf M Dekkers
    European Journal of Endocrinology.2024; 190(5): G25.     CrossRef
  • European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency
    Felix Beuschlein, Tobias Else, Irina Bancos, Stefanie Hahner, Oksana Hamidi, Leonie van Hulsteijn, Eystein S Husebye, Niki Karavitaki, Alessandro Prete, Anand Vaidya, Christine Yedinak, Olaf M Dekkers
    The Journal of Clinical Endocrinology & Metabolism.2024; 109(7): 1657.     CrossRef
  • Safely Withdrawing Glucocorticoid Therapy: A Case-Based Approach
    Mohammed Alenazi, Khaled Aldahmani, Syed Ali Imran
    Journal of Diabetes and Endocrine Practice.2024; 07(03): 129.     CrossRef
  • Secondary Adrenal Insufficiency: Recent Updates and New Directions for Diagnosis and Management
    Lucinda M. Gruber, Irina Bancos
    Endocrine Practice.2022; 28(1): 110.     CrossRef
  • Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study
    Andrew Menzies-Gow, Mark Gurnell, Liam G Heaney, Jonathan Corren, Elisabeth H Bel, Jorge Maspero, Timothy Harrison, David J Jackson, David Price, Njira Lugogo, James Kreindler, Annie Burden, Alex de Giorgio-Miller, Kelly Padilla, Ubaldo J Martin, Esther G
    The Lancet Respiratory Medicine.2022; 10(1): 47.     CrossRef
  • Development and Resolution of Secondary Adrenal Insufficiency after an Intra-Articular Steroid Injection
    Jia Wei Tan, Sachin K. Majumdar, Osamu Isozaki
    Case Reports in Endocrinology.2022; 2022: 1.     CrossRef
  • Long‐term corticosteroid use, adrenal insufficiency and the need for steroid‐sparing treatment in adult severe asthma
    M. Gurnell, L. G. Heaney, D. Price, A. Menzies‐Gow
    Journal of Internal Medicine.2021; 290(2): 240.     CrossRef
  • Glucocorticoid Withdrawal—An Overview on When and How to Diagnose Adrenal Insufficiency in Clinical Practice
    Katarzyna Pelewicz, Piotr Miśkiewicz
    Diagnostics.2021; 11(4): 728.     CrossRef
  • Morning Serum Cortisol as a Predictor for the HPA Axis Recovery in Cushing’s Disease
    Q. Cui, D. Liu, B. Xiang, Q. Sun, L. Fan, M. He, Y. Wang, X. Zhu, H. Ye, Giorgio Borretta
    International Journal of Endocrinology.2021; 2021: 1.     CrossRef
  • Dexamethasone-related adrenal insufficiency in patients with brain and skull base tumours
    H. Benghiat, P. Sanghera, D. Stange, P. Nightingale, A. Hartley, M.W O’Reilly, N. Nundall, H. Currie, M. Ali, G. Cruickshank, D. Spooner, A. Toogood
    Supportive Care in Cancer.2018; 26(12): 4031.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • The unresolved riddle of glucocorticoid withdrawal
    F. Guerrero Pérez, A. P. Marengo, C. Villabona Artero
    Journal of Endocrinological Investigation.2017; 40(11): 1175.     CrossRef
  • Lessons from iatrogenic Cushing syndrome in children
    Betty P Messazos, Margaret R Zacharin
    Journal of Paediatrics and Child Health.2016; 52(12): 1106.     CrossRef
Close layer
Case Reports
Adrenal gland
Allgrove (Triple A) Syndrome: A Case Report from the Kashmir Valley
Raiz Ahmad Misgar, Nazir Ahmad Pala, Mahroosa Ramzan, Arshad Iqbal Wani, Mir Iftikhar Bashir, Bashir Ahmad Laway
Endocrinol Metab. 2015;30(4):604-606.   Published online December 31, 2015
DOI: https://doi.org/10.3803/EnM.2015.30.4.604
  • 4,531 View
  • 39 Download
  • 10 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   

Allgrove (Triple A) syndrome is a rare autosomal recessive disorder characterized by cardinal features of adrenal insufficiency due to adrenocorticotropic hormone (ACTH) resistance, achalasia, and alacrimia. It is frequently associated with neurological manifestations like polyneuropathy. Since its first description by Allgrove in 1978, approximately 100 cases have been reported in the literature. Here we report an 18-year-old boy diagnosed as having Allgrove syndrome, with ACTH resistant adrenal insufficiency, achalasia, alacrimia, and severe motor polyneuropathy. Alacrimia was the earliest feature evident at the age of 8 years. He presented with achalasia and adrenal insufficiency at 12 and 18 years respectively and developed neurological symptoms in the form of severe muscle wasting at the age of 15 years. Patients with Allgrove syndrome usually manifest adrenal insufficiency and achalasia during first decade of life. Our patient manifested adrenal insufficiency and achalasia in the second decade and manifested neurological dysfunction before adrenal dysfunction.

Citations

Citations to this article as recorded by  
  • Child Neurology: Allgrove Syndrome
    Juhi Gupta, Sayoni Roy Chowdhury, Prashant Jauhari, Kaushik Ragunathan, Biswaroop Chakrabarty, Vandana Jain, Sheffali Gulati
    Neurology.2024;[Epub]     CrossRef
  • Don’t forget Allgrove syndrome in adult patients as a bulbar-ALS mimicker
    Martina Vigano’, Vittorio Mantero, Paola Basilico, Fiammetta Pirro, Dario Ronchi, Alessio Di Fonzo, Andrea Salmaggi
    Neurological Sciences.2023; 44(10): 3703.     CrossRef
  • Triple A (Allgrove) syndrome due to AAAS gene mutation with a rare association of amyotrophy
    Satyam Singh Jayant, Rahul Gupta, Kanhaiya Agrawal, Liza Das, Pinaki Dutta, Anil Bhansali
    Hormones.2021; 20(1): 197.     CrossRef
  • Allgrove syndrome with amyotrophy
    Míriam Carvalho Soares, Otávio Gomes Lins, José Ronaldo Lima de Carvalho, Cláudia Cristina de Sá, Vanessa Van der Linden, Anna Paula Paranhos Miranda Covaleski
    Practical Neurology.2021; : practneurol-2021-003192.     CrossRef
  • Triple A syndrome (Allgrove syndrome) – A journey from clinical symptoms to a syndrome
    Prakarti Yadav, Deepak Kumar, GopalK Bohra, MahendraK Garg
    Journal of Family Medicine and Primary Care.2020; 9(5): 2531.     CrossRef
  • Case report of a familial triple: a syndrome and review of the literature
    Federica Gaiani, Pierpacifico Gismondi, Roberta Minelli, Giovanni Casadio, Nicola de’Angelis, Fabiola Fornaroli, Gian Luigi de’Angelis, Marco Manfredi
    Medicine.2020; 99(22): e20474.     CrossRef
  • Clinical and genetic characterisation of a series of patients with triple A syndrome
    Erdal Kurnaz, Paolo Duminuco, Zehra Aycan, Şenay Savaş-Erdeve, Nursel Muratoğlu Şahin, Melişah Keskin, Elvan Bayramoğlu, Marco Bonomi, Semra Çetinkaya
    European Journal of Pediatrics.2018; 177(3): 363.     CrossRef
  • Clinical heterogeneity and molecular profile of triple A syndrome: a study of seven cases
    Kanika Singh, Ratna Dua Puri, Pratibha Bhai, Archana Dayal Arya, Garima Chawla, Renu Saxena, Ishwar C. Verma
    Journal of Pediatric Endocrinology and Metabolism.2018; 31(7): 799.     CrossRef
  • Clinical and molecular report of c.1331 + 1G > A mutation of the AAAS gene in a Moroccan family with Allgrove syndrome: a case report
    H. Berrani, T. Meskini, M. Zerkaoui, H. Merhni, S. Ettair, A. Sefiani, N. Mouane
    BMC Pediatrics.2018;[Epub]     CrossRef
Close layer
A Case of Primary Adrenal Insufficiency in a Patient with Acquired Immunodeficiency Syndrome.
Jae Ho Choi, Suk Chon, Yu Chul Hwang, Jun Seong Son, Seung Joon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong Taek Woo, Sung Woon Kim, Jin Woo Kim, Young Seol Kim, In Kyung Jeong
Endocrinol Metab. 2011;26(3):253-257.   Published online September 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.3.253
  • 2,332 View
  • 24 Download
  • 1 Crossref
AbstractAbstract PDF
The adrenal gland is the most commonly involved endocrine organ in patients infected with the human immunodeficiency virus (HIV). Adrenal function abnormality is more common in HIV patients than in the general population. It is important to recognize the condition of adrenal insufficiency, as this adrenal disorder may prove fatal if left untreated. Herein, we report a case of primary adrenal insufficiency in a 37-year-old male patient with acquired immunodeficiency syndrome. The patient complained of fever, general weakness, and fatigue. Impaired adrenal function was noted in the rapid ACTH stimulation test. After steroid supplementation, the patient's symptoms were improved. Therefore, HIV care physicians should ascertain adrenal dysfunction in HIV patients when they complain of fever and general weakness.

Citations

Citations to this article as recorded by  
  • A Case Report of Adrenal Insufficiency Treated with Korean Medicine
    Young-ji Kim, Jung-yeon Kwon, Ho-yeon Go, Kyung-hwan Kong
    The Journal of Internal Korean Medicine.2017; 38(5): 583.     CrossRef
Close layer
A Case Report of Bilateral Adrenocortical Carcinoma Complicated by Adrenal Insufficiency.
Min Joo Kim, Jung Hee Kim, Tae Young Kim, Sang Wan Kim
Endocrinol Metab. 2011;26(3):243-247.   Published online September 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.3.243
  • 2,186 View
  • 30 Download
  • 2 Crossref
AbstractAbstract PDF
Adrenocortical carcinoma is often functional and presents with signs and symptoms of adrenal steroid hormone excess. Adrenal insufficiency secondary to bilateral adrenocortical carcinoma is a particularly rare complication. We recently encountered a case of bilateral adrenocortical carcinoma complicated by adrenal insufficiency. A 52-year-old male was transferred to this hospital complaining of general weakness and weight loss. A bilateral adrenal mass was detected on abdomen CT. Plasma cortisol and aldosterone failed to rise during the rapid ACTH stimulation test. The CT-guided adrenal biopsy revealed findings consistent with adrenocortical carcinoma. Left hemiparesis was developed and brain metastasis was detected via brain MRI. Despite the application of gamma knife surgery and chemotherapy, the disease progressed and the patient died.

Citations

Citations to this article as recorded by  
  • Bilateral Adrenocortical Carcinoma Presenting as Acute Adrenal Insufficiency
    Anshita Aggarwal, Aprajita Verma, Aparajita Roy, Bindu Kulshreshtha
    European Endocrinology.2020; 16(2): 172.     CrossRef
  • A Case of Bilateral ACTH-independent Adrenal Adenomas with Cushing's Syndrome Treated by Ipsilateral Total and Contralateral Partial Laparoscopic Adrenalectomy
    Seung Ah Park, Dong min Jung, Soon young Kim, Nan Young Choi, Tae-jun Kim, Yong kyun Kim, Seong kyun Na, Chul Sik Kim, Seong Jin Lee, Sung-Hee Ihm, Jun Goo Kang
    The Korean Journal of Obesity.2013; 22(4): 254.     CrossRef
Close layer
Original Article
No Significance of the Free Cortisol Index Compared to Total Cortisol in Critically Ill Patients.
Kyung Won Kim, Sang Wan Kim, Hee Joung Kim, Chan Soo Shin, Sung Jae Park, Gil Joon Suh, Seong Yeon Kim
Endocrinol Metab. 2011;26(2):120-125.   Published online June 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.2.120
  • 2,098 View
  • 22 Download
  • 1 Crossref
AbstractAbstract PDF
BACKGROUND
Some patients exhibit an inadequate response of cortisol to stressful conditions; this state is known as critical illness-related corticosteroid insufficiency. These patients have low serum binding protein concentrations, thereby suggesting that total serum cortisol may not be reflective of circulating cortisol activity. As the free cortisol index (FCI = total cortisol/corticosteroid-binding globulin) has been correlated with serum free cortisol, we measured FCI in Korean patients for the first time. In this study, we attempted to determine whether FCI was superior to total cortisol in predicting 30-day mortality. METHODS: We recruited 65 critically ill patients with relatively high Acute Physiology, Age and Chronic Health Evaluation (APACHE III) scores. Fourteen patients with pituitary disease but normal pituitary function were recruited from outpatient clinics. Total cortisol and corticosteroid-binding globulin were measured in patients and controls during the short Synacthen test. RESULTS: The basal cortisol level and basal FCI level were higher in patients (n = 65) than in healthy controls (P < 0.001, respectively). We found that total cortisol was strongly correlated with FCI (P < 0.001) in critically ill patients; however, neither total cortisol nor FCI were associated with 30-day mortality among patients. Only severe clinical criteria (such as APACHE-III scores and low albumin) were associated with 30-day mortality. CONCLUSION: Our results do not suggest that FCI is more accurate than total cortisol in predicting clinical outcomes in critically ill patients.

Citations

Citations to this article as recorded by  
  • No Significance of the Free Cortisol Index Compared to Total Cortisol in Critically Ill Patients
    Doo-Man Kim
    Endocrinology and Metabolism.2011; 26(2): 118.     CrossRef
Close layer
Case Reports
Primary Bilateral Adrenal Non-Hodgkin's Lymphoma Presented with Adrenal Insufficiency: A Case Report.
Eun Young Lee, Kyoung Min Kim, Kwang Joon Kim, Songmi Noh, Jin Seok Kim, Woo Ik Yang, Sung Kil Lim
Endocrinol Metab. 2011;26(1):101-105.   Published online March 1, 2011
DOI: https://doi.org/10.3803/EnM.2011.26.1.101
  • 1,987 View
  • 24 Download
  • 1 Crossref
AbstractAbstract PDF
Primary adrenal lymphoma is a very rare disease and it is known to have a poor prognosis. We report here on a case of primary adrenal insufficiency that was secondary to primary bilateral adrenal lymphoma. A 54-year old man was hospitalized because of easy fatigability, weight loss and consistent malaise for 6 months. The physical examination revealed hyperpigmentation on the anterior chest and hypotension. According these findings and symptoms, we did a rapid ACTH stimulation test with a clinical suspicion of adrenal insufficiency. He showed an inadequate adrenal response and so he was diagnosed with adrenal insufficiency. The abdominal CT images showed bilateral huge adrenal masses and increased uptake of the adrenal glands on PET. The pathologic diagnosis by ultrasound-guided gun biopsy of the right adrenal gland was diffuse large B cell lymphoma. The patient was administered combination chemotherapy with the R-CHOP regimen, and after 8-cycles of chemotherapy, he achieved complete remission of tumor according to the image studies and he recovered his adrenal function. Primary adrenal lymphoma, although a rare disease, should be considered in patients with bilateral enlargement of the adrenal glands and when the adrenal glands show increased uptake on a PET scan, and especially there is adrenal insufficiency.

Citations

Citations to this article as recorded by  
  • Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell Lymphoma: A multi-institution retrospective analysis and systematic review
    John Xie, Albert Jang, Motohide Uemura, Shigeaki Nakazawa, Teresa Calimeri, Andres JM Ferreri, Shuang R. Chen, Janet L. Schmid, Theresa C. Brown, Francisco Socola, Hana Safah, Nakhle S. Saba
    Leukemia Research Reports.2021; 16: 100263.     CrossRef
Close layer
A Case of Pituitary Macroadenoma Accompanied with CRH Deficiency.
Yoo Jung Nahm, Jin Soo Kim, Keun Jong Cho, Uk Hyun Kil, Sung Yong Woo, Sung Rae Kim, Soon Jib Yoo, Sung Koo Kang, Ho Young Son
J Korean Endocr Soc. 2006;21(2):153-157.   Published online April 1, 2006
DOI: https://doi.org/10.3803/jkes.2006.21.2.153
  • 1,878 View
  • 16 Download
AbstractAbstract PDF
Pituitary tumor can be accompanied with various pituitary hormone abnormalities. Pituitary tumors can be divided into functioning or nonfunctioning tumors. A functioning pituitary tumor, via the oversecretion of pituitary hormones, causes diverse clinical features. A nonfunctioning pituitary tumor can be accompanied with pituitary dysfunction and this may be due to compression or destruction of normal pituitary tissue, suppression of the pituitary portal system or direct damage to the hypothalamus. Corticotropin-releasing hormone (CRH) deficiency, which is caused by defects in the synthesis or release of CRH, is a cause of secondary adrenocortical insufficiency. The clinical presentations are hypoglycemia, weight loss, anemia, weakness, nausea, vomiting and hyponatremia. Acquired CRH deficiency has also been suggested to occur based on a lack of adrenocorticotropic hormone (ACTH) response to insulin-induced hypoglycemia, but there is a normal ACTH response to exogenous CRH. We experienced a case of a woman with pituitary macroadenoma accompanied with CRH deficiency. We report here on this case with the review of the literature.
Close layer

Endocrinol Metab : Endocrinology and Metabolism
TOP